Correction to: Activatable Protein Nanoparticles for Targeted Delivery of Therapeutic Peptides (Advanced Materials, (2018), 30, 7, (1705383), 10.1002/adma.201705383)

Adv. Mater. 2018, 30, 1705383 In Figure b, P6 was lined in the reverse direction, and in Figures c and a, the interactions between P1 and P2, and P3 and P4 should have been parallel. The findings and conclusions presented in the original article are not affected. The corrected figures are shown here: (Figure presented.) Design of APNPs. a) Function and sequences of modular peptides used in the study. b) Schematic of polypeptides containing functional modular motifs. c) Formation and activation of APNPs. APNPs are self-assembled through pairwise coiled-coil dimerization and activated by proteases in disease microenvironment. Blue lines represent PEG molecules. (Figure presented.) TfR-Mel-APNPs for targeted delivery to tumors. a) Schematic of TfR-Mel-APNPs. b) In vivo quantitative distribution of Mel-APNPs with and without target ligand RTIGPSV. When tumor volume reached ≈200 mm³, mice were grouped and received treatment of AF750-labeled APNPs. 24 h later, mice were euthanized. The tumors were harvested and subjected to IVIS imaging. Fluorescence intensity in the ischemic region was determined using Living Image 3.0.